WM-1119 is a highly potent and selective KAT6A inhibitor, with an IC50 of 0.25 μM for KAT6A in lymphoma cells, the binding KD values of WM-1119 with KAT6A, KAT5 and KAT7 are 2 nM, 2.2 μM, 0.5 μM , respectively. WM-1119 induces cell cycle exit and cellular senescence without causing DNA damage. Treatment of MEFs with WM-1119 results in cell cycle arrest in G1 and a senescence phenotype. WM-1119 arrests the progression of lymphoma in mice. WM-1119 is well-tolerated; mice show no generalized ill effects and weight loss is not observed. The proportion and overall number of tumour cells is substantially reduced by WM-1119 treatment (four times per day).
Molecular Weight | 389.38 |
Formula | C18H13F2N3O3S |
CAS Number | 2055397-28-7 |
Solubility (25°C) | DMSO 80 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Histone Acetyltransferase Products |
---|
AU-18069
AU-18069 is a CBP/p300 HAT inhibitor that can be used in studies related to hematological and solid tumors. |
KAT modulator-1
KAT modulator-1 is a KAT modulator. |
KAT6-IN-1
KAT6-IN-1 is a potent KAT6 inhibitor. |
MC4171
MC4171 is a selective KAT8 inhibitor (IC50=8.1 µM). |
MOZ-IN-3
MOZ-IN-3 is a KAT6A (MOZ) acetyltransferase inhibitor (IC50: 30 nM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.